Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B
Authors:
Open Access
- 18 August 2022
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (6) , 1515-1524
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography–defined subclinical cirrhosisHepatology, 2015
- Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trialTrials, 2014
- Traditional Chinese Medicine (TCM) for fibrotic liver disease: Hope and hypeJournal of Hepatology, 2014
- Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis BJournal of Hepatology, 2014
- Long-term therapy of chronic hepatitis B reverses cirrhosisNature Reviews Gastroenterology & Hepatology, 2013
- Liver biopsy†Hepatology, 2009
- Grading and staging systems for inflammation and fibrosis in chronic liver diseasesJournal of Hepatology, 2007
- Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluationLiver International, 2007
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995